Rajesh Shrotriya, chairman, president and CEO of Spectrum, said: “The sale of these non-core assets provides additional non-dilutive funding which will be used to further fund the advancement of our late stage clinical programs.”
Rajesh Shrotriya, chairman, president and CEO of Spectrum, said: “The sale of these non-core assets provides additional non-dilutive funding which will be used to further fund the advancement of our late stage clinical programs.”